Hanmi Pharmaceutical Launches Internal Anti-Smoking Campaign for Employees
Seoul, South Korea – Hanmi Pharmaceutical, a leading pharmaceutical company, announced on the 24th that it will be organizing an anti-smoking campaign exclusively for its internal employees. This initiative comes following the recent release of ‘Nocotine,’ a breakthrough specialist drug for smoking cessation treatment containing varenicline that was introduced to the market in May. Developed and manufactured by Hanmi, Nocotine aims to provide effective support in helping individuals quit smoking.
In an effort to promote employee engagement, Hanmi Pharmaceutical has devised a comprehensive incentive program for those participating in the anti-smoking campaign. Executives and employees who actively take part will earn wellness points and gift cards, encouraging their voluntary involvement for a specific duration. Furthermore, as a gesture of appreciation, Hanmi will contribute donations upon the successful completion of all anti-smoking programs.
Recognizing the challenges faced by smokers attempting to quit, Hanmi Pharmaceutical is committed to offering comprehensive support to executives and staff members throughout their journey. This support includes medical treatment, counseling services, and guidance on the appropriate use of nicotine-replacement medications.
An official spokesperson from Hanmi Pharm stated, “As a pharmaceutical company that prioritizes the well-being of individuals, it is our inherent responsibility to actively contribute to smoking cessation efforts.”
As the campaign unfolds, Hanmi Pharmaceutical continues to highlight its dedication to improving public health and striving towards a smoke-free society. This bold step forward in advocating for smoking cessation underscores the company’s commitment to fostering a healthier and more sustainable future.
Photo = Hanmi Pharmaceutical
Hanmi Pharm (CEO Park Jae-hyun) announced on the 24th that it will hold an anti-smoking campaign for internal employees with the recent launch of ‘Nocotine’. Nocotine is a specialist drug for smoking cessation treatment containing varenicline, launched in May, and is a smoking cessation medicine developed and manufactured by Hanmi.
Hanmi Pharmaceutical plans to encourage voluntary participation by providing wellness points and gift cards to executives and employees who participate in the anti-smoking campaign for a certain period of time, and presenting donations upon completion of all anti-smoking programs. In addition, it intends to provide various support to executives and staff members who have difficulty quitting smoking by providing medical treatment and counselling, and guidance on taking medications such as nicotine.
An official from Hanmi Pharm said, “As a pharmaceutical company responsible for people’s health, it is a natural responsibility to participate in helping people stop smoking.”
#Hanmi #Pharm #conducts #internal #antismoking #campaign #antismoking #drug #Nocotine
